Granted Patent
B2
US 12,358,986 · App. 17/436,857 · Granted Jul 15, 2025
Anti-cancer combination therapies comprising CTLA-4 and PD-1 blocking agents
Inventors:
Drake LaFace (Half Moon Bay, CA); Juha Punnonen (Belmont, CA); Edward Bowman (Bowman, CA); David Bauche (San Mateo, CA); Alissa Chackerian (Sunnyvale, CA); Jeffery Grein (Sunnyvale, CA); Smita Mauze (Belmont, CA); Anandi Sawant (Sunnyvale, CA); Lakshmanan Annamalai (Dublin, CA)
Assignee:
Merck Sharp & Dohme LLC
C07K16/2818A61P35/00A61K39/00A61K2039/507A61K2039/545C07K16/00C07K16/2803C07K2317/21C07K2317/22C07K2317/51C07K2317/515C07K2317/565C07K2317/567C07K2317/71C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.
Claims (6)
1. A method for treating a cancer in an individual with an anti-PD-1/anti-CTLA-4 antibody combination without causing moderate to severe skin or gut inflammatory immune-related toxicities, the method comprising administering a combination of:
an anti-PD-1 antibody with effector function comprising a heavy chain (HC) comprising the amino acid sequence set forth in SEQ ID NO: 27 and a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 28 and an effecter-silent anti-CTLA-4 antibody with reduced or no measurable effector function comprising (i) an HC having a HC variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 7 and an HC constant domain comprising the amino acid sequence set forth in SEQ ID NO: 38, 39, 40, 41, 42, 43, 44, 116, or 117 and (ii) a LC having an LC variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 8 and an LC constant domain comprising the amino acid sequence set forth in SEQ ID NO: 57, which treats the cancer in the individual without causing moderate to severe skin or gut inflammatory immune-related toxicities.
2. The method of claim 1 , wherein the anti-CTLA-4 antibody is administered at a dose comprising more than 1 mg/kg or a fixed dose that does not depend on the individual's weight that is 100 mg or more.
3. The method of claim 1 , wherein the anti-PD-1 antibody is administered at a dose comprising (i) 2 or 3 mg/kg or a fixed dose that does not depend on the individual's weight that is 200 mg, (ii) more than 3 mg/kg or a fixed dose that does not depend on the individual's weight that is more than 200 mg, or (iii) a fixed dose that does not depend on the individual's weight that is between about 200 mg to about 400 mg.
4. The method of claim 1 , wherein the cancer is melanoma, non-small cell lung cancer, head and neck cancer, urothelial cancer, breast cancer, gastrointestinal cancer, multiple myeloma, hepatocellular cancer, non-Hodgkin lymphoma, renal cancer, Hodgkin lymphoma, mesothelioma, ovarian cancer, small cell lung cancer, esophageal cancer, anal cancer, biliary tract cancer, colorectal cancer, cervical cancer, thyroid cancer, or salivary cancer.
5. The method of claim 1 , wherein the cancer is pancreatic cancer, bronchus cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.
Assignments (2)
MERGER
Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 7, 2021
From: LAFACE, DRAKE; PUNNONEN, JUHA; BOWMAN, EDWARD; BAUCHE, DAVID; CHACKERIAN, ALISSA; GREIN, JEFFERY; MAUZE, SMITA; SAWANT, ANANDI; ANNAMALAI, LAKSHMANAN
To: MERCK SHARP & DOHME CORP.
Reel/Frame 057508/0553 →
Continuity (2)
Provisional Application
62817749
· Mar 13, 2019
References Cited (108)
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 6984720B1
· Korman et al.
· 2006
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8491895B2
· Hanson et al.
· 2013
[cited by applicant]
US 8969526B2
· Baehner
· 2015
[cited by applicant]
US 9296815B2
· D'angelo
· 2016
[cited by applicant]
US 9708406B2
· Zhang
· 2017
[cited by applicant]
US 9987500B2
· Papadopoulos et al.
· 2018
[cited by applicant]
US 20060235208A1
· Lazar et al.
· 2006
[cited by applicant]
US 20180319892A1
· Feltquate
· 2018
[cited by examiner]
US 20200262922A1
· Bhattacharya
· 2020
[cited by examiner]
US 20210047409A1
· Lala
· 2021
[cited by examiner]
JP 2006512407A
· 2006
[cited by applicant]
JP 2017515859A
· 2017
[cited by applicant]
WO 199428027A1
· 1994
[cited by applicant]
WO 2004029207A2
· 2004
[cited by applicant]
WO 2004099249A2
· 2004
[cited by applicant]
WO 2006121168A1
· 2006
[cited by applicant]
WO 2008071447A2
· 2008
[cited by applicant]
WO 2009025846A2
· 2009
[cited by applicant]
WO 2009030285A1
· 2009
[cited by applicant]
WO 2009114335A2
· 2009
[cited by applicant]
WO 2010081173A2
· 2010
[cited by applicant]
WO 2012130831A1
· 2012
[cited by applicant]
WO 2014089113A1
· 2014
[cited by applicant]
WO 2015112800A1
· 2015
[cited by applicant]
WO 2015176033A1
· 2015
[cited by applicant]
WO 2016196237A1
· 2016
[cited by applicant]
WO 2017087587A1
· 2017
[cited by applicant]
WO 2017087588A1
· 2017
[cited by applicant]
WO 2017087589A2
· 2017
[cited by applicant]
WO WO2017087870A1
· 2017
[cited by examiner]
WO 2017118675A1
· 2017
[cited by applicant]
WO 2018085555A1
· 2018
[cited by applicant]
WO 2018183408A1
· 2018
[cited by applicant]
WO 2018222949A1
· 2018
[cited by applicant]
WO 2019023482A1
· 2019
[cited by applicant]
Das R, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. Feb. 1, 2015;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub Dec. 24, 2014. PMID: 25539810; PM…
[cited by examiner]
Schlothauer T, et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. Oct. 2016;29(10):457-466. doi: 10.1093/protein/gzw040. Epub Aug. 29, 201…
[cited by examiner]
Hammers HJ, et al. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. Dec. 1, 2017;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985.…
[cited by examiner]
Sozzi, G., et al. “MA04. 06 PD-1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody-Fc/FcR Interaction.” Journal of Thoracic Oncology 13.10 (2018): S368. (Year: 2018).
[cited by examiner]
Okan Cakir M, et al. Hyperprogression after immunotherapy: A comprehensive review. J Buon. Nov.-Dec. 2019;24(6):2232-2241. PMID: 31983088. (Year: 2019).
[cited by examiner]
Watanabe T, et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. May 2023; 114(5):1859-1870. doi: 10.1111/cas.15756. Epub Feb. 26, 2023. P…
[cited by examiner]
Corraliza-Gorjón, Isabel et al., New Strategies Using Antibody Combinations to increase Cancer Treatment effectiveness, Frontiers in Immunology, vol. 8, Article 1804, 1-31, 2017.
[cited by applicant]
Markham, Anthony et al., Cemiplimab: First Global Approval, Drugs, 78, 1841-1846, 2018.
[cited by applicant]
Mould, Diane R. et al., Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies, BioDrugs, 24(1), 23-39, 2010.
[cited by applicant]
Bauché, David et al., Antitumor efficacy of combined CTLA4/ PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions, J Immunother Cancer, 2020, 1-10, 8:e001584.
[cited by applicant]
Deng, Rong et al., Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor, mAbs, 2016, 593-603, 8:3.
[cited by applicant]
Schlothauer, Tilman et al., Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions, Protein Engineering, Design & Selection, 2016, 457-466, 29(10).
[cited by applicant]
Wang, Xinhua et al., IgG Fc engineering to modulate antibody effector functions, Protein Cell, 2018, 63-73, 9(1).
[cited by applicant]
Madrenas, Joaquín et al., Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand, J Immunol, 172(10), 5948-5956, 2004.
[cited by applicant]
Bengsch, et al., Success of immune checkpoint blockade therapies—mechanisms and implications for hepatology, Z Gastroenterol, 57, pp. 74-86, 2019.
[cited by applicant]
Topalian et al., Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, vol. 27, pp. 450-461, 2015.
[cited by applicant]
Wolchok et al., Nivolumab plus Ipilimumab in Advanced Melanoma, The New England Journal of Medicine, vol. 369(2), pp. 122-133, 2013.
[cited by applicant]
Agata et al., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, International Immunology, 1996, pp. 765-772, vol. 8, No. 5.
[cited by applicant]
Angal et al., A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody, Molecular Immunology, 1993, pp. 105-108, vol. 30(1).
[cited by applicant]
Armour et al., Recombinant Human IgG Molecules Lacking Fcy receptor I Binding and Monocyte Triggering Activities, Eur. J. Immunol., 1999, pp. 2613-2624, 29.
[cited by applicant]
Balzano, Christine et al., CTLA-4 and CD28: Similar Proteins, Neighbouring Genes, Int. J. Cancer, 1992, 28-32, Suppl. 7.
[cited by applicant]
Beiboer, Sigrid H. W. et al., Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent, J. Mol…
[cited by applicant]
Bennett et al., Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses, The …
[cited by applicant]
Bertrand, Anne et al., Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Medicine, 2015, 1-14, 13:211.
[cited by applicant]
Blank et al., Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections, Cancer Immunol. Immunother., 2007, pp. 739-745, vol. 56(5).
[cited by applicant]
Blank, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy, Cancer Immunol. Immunother., 2005, pp. 307-314, 54.
[cited by applicant]
Brown, Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production, J. Immunol., 2003, pp. 1257-1266, vol. 170.
[cited by applicant]
Béranger, et al., Ed. Ginetoux, Correspondence between the IMGT unique numbering for C-DOMAIN, the IMGT exon humbering, the Eu and Kabat numberings: Human IGHG, Created: May 17, 2001, Version: Aug. 6, 2016, which is acc…
[cited by applicant]
Carter et al., PD-1:PD-L Inhibitory Pathway Affects Both CD4 Plus and CD8 Plus and CD8 Plus T Cells and is overcome by IL-2, Eur. J. Immunol., 2002, pp. 634-643, 32.
[cited by applicant]
Cayatte, Corinne et al., Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease, Clinical and Translational Gastroenterology, 2012, 1-10, 3:e10.
[cited by applicant]
Chothia and Lesk et al., Canonical Structures for the Hypervariable Regions of Immunoglobins, J. Mol. Biol., 1987, 901-917, 196.
[cited by applicant]
Chothia et al., Conformations of immunoglobin hypervariable regions, Nature, 1989, 877-883, 342.
[cited by applicant]
Common Terminology Criteria for Adverse events (CTCAE) Version 5.0, published Nov. 27, 2017, by the U.S. Department of health and Human Services, 155 pages.
[cited by applicant]
Dong et al., B7-H1 pathway and its role in the evasion of tumor immunity, J. Mol. Med., 2003, pp. 281-287, 81.
[cited by applicant]
Edelman, Gerald M. et al., The Covalent Structure of an Entire gammaG Immunoglobulin Molecule, Proc. Natl. Acad. Sci. USA, 1969, 78-85, 63.
[cited by applicant]
Freeman et al., Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation, J. Exp. Med., 2000, pp. 1027-1034, vol. 192.
[cited by applicant]
Hamid et al., Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma, New Eng. J. Med., 2013, 134-144, 369(2).
[cited by applicant]
Hui, Enfu et al., T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition, Science, 2017, 1428-1433, 355.
[cited by applicant]
Ingram, Jessica R. et al., Anti-CTLA-4 therapy requires an Fc domain for efficacy, Proc. Natl. Acad. Sci. USA, 2018, 3912-3917, 115.
[cited by applicant]
Ishida et al., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, The EMBO Journal, 1992, pp. 3887-3895, vol. 11(11).
[cited by applicant]
Wai, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. USA, 2002, pp. 12293-12297, vol. 99.
[cited by applicant]
Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 19 pages.
[cited by applicant]
Kabat, The Structural Basis of Antibody Complementarity, Adv. Prot. Chem., 1978, 1-75, 32.
[cited by applicant]
Kabat, Unusual Distributions of Amino Acids in Complementarity-determining (Hypervriable) Segment of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites, J. Biol…
[cited by applicant]
Kamphorst, Alice O., Rescue of exhaused CD8 T cells by PD-1 targeted therapies is CD28-dependent, Science, 2017, 1423-1427, 355(6332).
[cited by applicant]
Klimka, A. et al., Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning, British Journal of Cancer, 2000, 252-260, 83(2).
[cited by applicant]
Konishi et al., B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression, Clin. Cancer Res., 2004, pp. 5094-5100, 10.
[cited by applicant]
Konitzer, Jennifer D. et al., Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro, PLoS One, 2015, 1-20, 10:e0145633.
[cited by applicant]
Korman, Alan J. et al., Abstract SY09-01: Next-generation anti-CTLA-4 antibodies, Cancer Research, 2017, 1-6, 77(13).
[cited by applicant]
Morrison, Sherie L. et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 1984, 6851-6855, 81.
[cited by applicant]
Murata, Ken-Ya et al., Expression of the Costimulatory Molecule BB-1, the Ligands CTLA-4 and CD28, and their MRNA in Inflammatory Myopathies, American Journal of Pathology, 1999, 453-460, 155.
[cited by applicant]
Nimmerjahn, FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity, Immunity, 2005, pp. 41-51, 23.
[cited by applicant]
Okazaki et al., New regulatory co-receptors: inducible co-stimulator and PD1, Curr. Opin. Immunol., 2002, pp. 779-782, 14.
[cited by applicant]
Package Insert and Label for Yervoy (Jul. 2018), 52 pages.
[cited by applicant]
Pai, Chien-Chun Steven et al., Tumon-conditional anti-CTLA4 uncouples antitumor efficacy from Immunotherapy-related toxicity, The Journal of Clinical Investigation, 2019, 349-363, 129.
[cited by applicant]
Rader et al., A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries, Proc. Natl. Acad. Sci. USA, 1998, pp. 8910-8915, 95.
[cited by applicant]
Ribas, Antoni et al., Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte-Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer, The Oncologist, 2007, 873-993, 12.
[cited by applicant]
Samaan, Mark A. et al., Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management, Nature Reviews / Gastroenterology & Hepatology, 2018, 222-234, 15.
[cited by applicant]
Schneider-Merck, Tanja et al., Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage, The …
[cited by applicant]
Schuurman et al., The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds, Molecular Immunology, 2001, pp. 1-8, vol. 38.
[cited by applicant]
Selby, Mark J. et al., Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells, Cancer Immunology Research, 2013, 32-42, 1.
[cited by applicant]
Shields, Robert L. et al., High Resolution Mapping of the Bidning Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and ReRn and Design of IgG1 Variants with Improved Binding to the FcyR*, The Journal of Biological Chemist…
[cited by applicant]
Simpson, Tyler R. et al., Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, The Journal of Experimental Medicine, 2013, 1695-1710, 210.
[cited by applicant]
Sondermann et al., The 3.2-Angstrom Crystal Structure of the Human IgG1 Fc Fragment-Fc gamma RIII Complex, Nature, 2000, pp. 267-273, 406.
[cited by applicant]
Vargas, Frederick Arce et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell, 2018, 649-663, 33.
[cited by applicant]
Waight, Jeremy D. et al., Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens, Cancer Cell, 2018, 1033-1047, 33.
[cited by applicant]
Xu, JL et al., Diversity in the CDR3 region of Vh is sufficient for most antibody specificities, Immunity, 2000, pp. 37-45, 13.
[cited by applicant]